Carisma Therapeutics Inc (CARM) USD0.001

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer. The Company seeks to apply the ability to engineer macrophages and monocytes, either in vivo or ex vivo. Its proprietary chimeric antigen receptor macrophages(CAR-M) platform uses CARs to redirect macrophages or monocytes against specific tumor associated antigens with the goal of targeted antitumor immunity. It is developing a pipeline of product candidates which includes CT-1119, In Vivo CAR-Macrophage: GPC3+ Solid Tumors, In Vivo CAR-Macrophage: Oncology Targets, and CT-2401 (Liver Fibrosis). CT-2401 is a product candidate in development for liver fibrosis, and CT-1119 is a mesothelin-targeted CAR-Monocyte that is designed to treat patients with advanced mesothelin-positive solid tumors, including pancreatic cancer, ovarian cancer, lung cancer, mesothelioma, and others.